Trial Profile
A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational
- Acronyms PREVAIL-Extension
- Sponsors Sunovion Pharmaceuticals
- 01 Sep 2022 Results published in the Current Medical Research and Opinion
- 24 May 2017 Results of post hoc analysis presented at the 170th Annual Meeting of the American Psychiatric Association
- 23 May 2016 Results published in the journal Depression and Anxiety, as per Sunovion media release.